SEC Form 4 · accession 0001209191-17-065245
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay T Flatley
Director
Period of report
Dec 12, 2017
Accepted (ET)
Dec 12, 2017 · 5:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 12, 2017 | C | 250,000 | — | A | 250,000 | I | See footnote |
| Common Stock | holding | — | — | — | 75,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A-1 Preferred StockF2,F1 | — | Dec 12, 2017 | C | 250,000 | D | — | — | Common Stock | 250,000 | 0 | I |
Explanation of responses
- F1The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
- F2The shares are held of record by The Flatley Family Trust, for which the Reporting Person serves as a trustee.